[Applying dose banding to the production of antineoplastic drugs: a narrative review of the literature].
The dosage of antineoplastic drugs has historically been based on individualized prescription and preparation according to body surface area or patient´s weight. Lack of resources and increased assistance workload in the areas where chemotherapy is made, are leading to the development of new systems to optimize the processing without reducing safety. One of the strategies that has been proposed is the elaboration by dose banding. This new approach standardizes the antineoplastic agents doses by making ranges or bands accepting a percentage of maximum variation. It aims to reduce processing time with the consequent reduction in waiting time for patients; to reduce errors in the manufacturing process and to promote the rational drug use. In conclusion, dose banding is a suitable method for optimizing the development of anticancer drugs, obtaining reductions in oncologic patients waiting time but without actually causing a favorable impact on direct or indirect costs.
Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia (Spain).. pablopehu@gmail.com.
Pablo
P
Pérez Huertas
Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia (Spain).. cueto_mar@gva.es.
Margarita
M
Cueto Sola
Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia (Spain).. escobar_pal@gva.es.
Paloma
P
Escobar Cava
Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia (Spain).. borrell_car@gva.es.
Carmela
C
Borrell García
Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia (Spain).. albert_asu@gva.es.
Asunción
A
Albert Marí
Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia (Spain).. lopez_edubri@gva.es.
Eduardo
E
López Briz
Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia (Spain).. poveda_josand@gva.es.
José Luis
JL
Poveda Andrés
D000465:Algorithms; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics; D012015:Reference Standards
D000970:Antineoplastic Agents